Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE). Currently, the toxicity of irAE is limiting...

Descripción completa

Detalles Bibliográficos

Autores principales:	Alisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, Ihor Arkhypov, Samantha Lasser, Jochen Utikal, Viktor Umansky
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Taylor & Francis Group 2023-12-01
Colección:	OncoImmunology
Materias:	Immune-related adverse events immunotherapy melanoma
Acceso en línea:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2247303
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!